Infectious Disease · Vaccines

The Test-Drive Meaning of “Approved”

Picture a car salesperson handing you a set of keys.

“Good news,” he says. “You’re approved.”

Approved for a test drive, that is. No one drives off the lot thinking they own the car. They think they have earned a chance to see if it is worth buying.

Keep that test drive in mind, because the word “approved” did a lot of work in last week’s Ebola headlines.

What the WHO’s Bundibugyo Ebola Vaccine Decision Actually Means

The World Health Organization approved clinical trials for two new Ebola vaccines while doctors try to control the biggest outbreak in the history of the Democratic Republic of the Congo.

Skim the news, and it sounds like another vaccine is headed for millions of arms. Read it closely, and it says something narrower. For anyone with hard questions about these vaccines, that narrower version is the useful one.

The WHO’s decision does not mean two new Bundibugyo Ebola vaccines have been proven safe and effective. It means the authorities have cleared them to enter clinical trials. The key questions about data, testing, and side effects are exactly what the trials are meant to answer.

New vaccines are needed for Bundibugyo Ebola, and Ervebo’s history shows how vaccine evidence builds over time.

The Questions Are the Whole Point

The skeptic’s checklist is fair:

For these two vaccines, the answer to all three is the same: that is what the trial is for.

WHO experts suggested adding both candidates to the Tumaini clinical trial in Congo. They will join the trial after getting national approvals. It marks the first time vaccines made for this form of Ebola will be tested during an outbreak.

Researchers expect vaccine trial results in early 2027.

In other words, nobody, including the WHO, can yet say how well these vaccines work or what side effects they may cause in the field. Anyone who says otherwise, in either direction, is guessing.

“Ebola” Is a Family Name

A licensed Ebola vaccine, called Ervebo, already exists. So why build new ones?

Because Ebola is not one virus; it is a group of related species, and a vaccine aimed at one may miss another.

Ervebo protects against the Zaire species but not against other species such as Sudan.

Why Bundibugyo Ebola Needs Its Own Answers

The current outbreak is caused by a different species, Bundibugyo, for which no vaccine or specific treatment exists.

The toll is steep. Nearly six months after it was declared, the outbreak has spread to eight provinces across Congo’s east and north, infected more than 10,500 people, and killed about half of them.

Researchers now test Ervebo in a full-scale human trial to see whether it offers any cross-protection against Bundibugyo.

What the Last Ebola Vaccine Trial Can Teach Us

The best preview of how these questions get answered is Ervebo’s own record, because it went through this exact process a decade ago.

How Ervebo Was Tested

During the West Africa outbreak, a trial in Guinea showed Ervebo’s effectiveness using ring vaccination.

Instead of vaccinating everyone, researchers vaccinated:

More than 9,000 adults were randomly assigned to receive the vaccine immediately or 21 days later.

The result:

Why “100 Percent” Needs Context

Here is where a careful reader should pause.

“One hundred percent” sounds like a guarantee. But the same report’s confidence interval, adjusted for multiple comparisons, ran from 14.4 percent to 100 percent.

Ten cases is a small number to build a headline on. The trial also had no placebo group, chosen for ethical reasons.

None of that made the result wrong. Preliminary results from a big ring-vaccination program in Congo in 2019 showed the vaccine was 97.5 percent effective. It stopped transmission compared to no vaccination.

But it shows why the most impressive number in a story deserves a second look.

What Real Side-Effect Data Looks Like

The side-effect data are just as useful.

In one study of 498 people, the most common reactions were:

Some problems showed up early. A Phase 1 study that started at a high dose caused arthritis and skin reactions in some people, and researchers halted that trial.

Across later placebo-controlled studies, most arthritis cases appeared within the first few weeks after vaccination, were mild to moderate, and resolved within several weeks.

Among 15,399 people vaccinated, there were two reports of anaphylaxis and two of serious fever linked to the vaccine. None were fatal.

That is what a real answer to “What are the side effects?” looks like. It is specific, it is numbered, it is sometimes uncomfortable — and it is published. It took years of trials to produce.

What Works While the Trial Runs

Bundibugyo isn’t waiting for early 2027. Fortunately, the defenses with the longest track record need no needle. Dr. Peter McCullough, a cardiologist and epidemiologist who formulated The Wellness Company’s Ultimate Spike Detox, wrote that the virus is “transmitted primarily through direct contact with the bodily fluids of moribund or deceased patients.” That single fact points to nearly every practical defense, and WHO guidance lines up with it:

Frequently Asked Questions About the Bundibugyo Ebola Vaccine Trials